União Europeia - polonês - EMA (European Medicines Agency)

astrazeneca ab - Саксаглиптин - diabetes mellitus, type 2 - leki stosowane w cukrzycy - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

astrazeneca ab - tamoxifeni citras - tabletki powlekane - 20 mg

Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

astrazeneca ab - goserelini acetas - implant podskórny - 3,6 mg

Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

astrazeneca ab - budesonidum - zawiesina do nebulizacji - 0,25 mg/ml

Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

astrazeneca ab - budesonidum - zawiesina do nebulizacji - 0,5 mg/ml

Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

astrazeneca ab - budesonidum - zawiesina do nebulizacji - 0,125 mg/ml

União Europeia - polonês - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - astma - preparaty do obturacyjne choroby dróg oddechowych, - fasenra jest wskazany jako uzupełnienie terapii u dorosłych pacjentów z ciężką eozynofilowe astmą, z niedostatecznie kontrolowanym, pomimo wysokich dawek wziewnych glikokortykosteroidów plus o przedłużonym działaniu beta-adrainomimetikov.

União Europeia - polonês - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - choroba płuc, przewlekła obturacyjna - preparaty do obturacyjne choroby dróg oddechowych, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

União Europeia - polonês - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - białaczka, limfocytowa, przewlekła, komórka b - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

União Europeia - polonês - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - białaczka, włochate komórki - Środki przeciwnowotworowe - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).